Home » Stocks » KPTI

Karyopharm Therapeutics, Inc. (KPTI)

Stock Price: $16.32 USD -0.31 (-1.84%)
Updated December 4, 3:43 PM EST - Market open

KPTI Stock Price Chart

Key Info

Market Cap 1.20B
Revenue (ttm) 91.08M
Net Income (ttm) -201.50M
Shares Out 73.47M
EPS (ttm) -2.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $16.32
Previous Close $16.62
Change ($) -0.31
Change (%) -1.84%
Day's Open 16.69
Day's Range 16.05 - 16.90
Day's Volume 1,363,471
52-Week Range 14.14 - 27.72

KPTI Stock News

PRNewsWire - 2 days ago

NEWTON, Mass., Dec. 1, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it wil...

CNBC - 5 days ago

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Anaplan and Autodesk

Other stocks mentioned: ADSK, PLAN, RPAY
PRNewsWire - 1 week ago

NEWTON, Mass., Nov. 25, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that foll...

PRNewsWire - 2 weeks ago

NEWTON, Mass., Nov. 20, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported it will pr...

Seeking Alpha - 2 weeks ago

Xpovio is showing good uptake after about a year on the market. The second line multiple myeloma indication will likely be added next Spring.

Seeking Alpha - 3 weeks ago

Recent advancements in readouts for Xpovio and Selinexor have yet to be reflected in market pricing, in our view. Karyopharm has had an in line quarter, where Xpovio sales were driven by new p...

PRNewsWire - 3 weeks ago

NEWTON, Mass., Nov. 12, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the ...

PRNewsWire - 1 month ago

NEWTON, Mass., Nov. 4, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that twent...

PRNewsWire - 1 month ago

NEWTON, Mass., Nov. 3, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Com...

Seeking Alpha - 1 month ago

Karyopharm Therapeutics, Inc. (KPTI) CEO Michael Kauffman on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 1 month ago

Karyopharm Therapeutics, Inc. (KPTI) CEO Michael Kauffman on Q3 2020 Results - Quick Version Earnings Call Transcript

Zacks Investment Research - 1 month ago

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 0.00% and -0.08%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead fo...

Benzinga - 1 month ago

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) increased 10.3% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 8.96% over the pas...

PRNewsWire - 1 month ago

NEWTON, Mass., Nov. 2, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial r...

PRNewsWire - 1 month ago

NEWTON, Mass., Nov. 2, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced positive t...

Zacks Investment Research - 1 month ago

Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 1 month ago

NEWTON, Mass., Oct. 26, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it wi...

PRNewsWire - 1 month ago

NEWTON, Mass., Oct. 6, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced an oral pr...

PRNewsWire - 2 months ago

NEWTON, Mass., Sept. 14, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc.

Zacks Investment Research - 2 months ago

Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.

PRNewsWire - 3 months ago

NEWTON, Mass., Sept. 2, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc.

Seeking Alpha - 3 months ago

Oncology Stocks Area Trading Materially Lower The Last 2 Months

Other stocks mentioned: BYSI, GTHX, URGN
Seeking Alpha - 3 months ago

Of a pool of 26 oncology stocks we track, with 1 exception, all (literally 25 of 26) are trading materially lower from the third week of June 2020.

Other stocks mentioned: BYSI, GTHX, URGN
PRNewsWire - 3 months ago

NEWTON, Mass., Aug. 21, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc.

Seeking Alpha - 4 months ago

Karyopharm Therapeutics, Inc. (KPTI) CEO Michael Kauffman on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -10.53% and 19.57%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for t...

PRNewsWire - 4 months ago

NEWTON, Mass., Aug. 4, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc.

Zacks Investment Research - 4 months ago

Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

NEWTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the U.S. Food and Drug Administ...

Seeking Alpha - 4 months ago

Karyopharm has a market cap under $1.5 billion, yet peak sales of Xpovio in just its first 3 indications could easily exceed that figure.

Seeking Alpha - 4 months ago

Karyopharm's XPOVIO Progress And Other News: The Good, Bad And Ugly Of Biopharma

GlobeNewsWire - 4 months ago

NEWTON, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that it has entered into a Cooperati...

GlobeNewsWire - 4 months ago

-- Preliminary Unaudited XPOVIO Net Product Sales of Approximately $18.5 Million for the  Second Quarter 2020 -- -- Strongest Quarterly XPOVIO Sales Since July 2019 Commercial Launch --

Seeking Alpha - 5 months ago

Karyopharm Stock Down From Peak Despite Commercial Progress And Strong Data Provides Investor Opportunity

GlobeNewsWire - 5 months ago

NEWTON, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the results of the Phase 2b SAD...

Zacks Investment Research - 5 months ago

Karyopharm (KPTI) gets FDA approval for label expansion of its marketed drug, Xpovio, in relapsed or refractory diffuse large B-cell lymphoma.

Benzinga - 5 months ago

The SPDR S&P 500 (NYSE: SPY) started off the week on a high note on Monday morning after a turbulent week of trading last week.

Other stocks mentioned: ARDS, CGC, DB, DRI, HSBC, NKE, UBS, ZGNX
GlobeNewsWire - 5 months ago

-- XPOVIO is Now the Only Single-Agent, Oral Therapy Approved for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, Including DLBCL Arising from Follicular L...

GlobeNewsWire - 5 months ago

-- Selinexor Demonstrates a Significant Survival Benefit in Patients with Relapsed or Refractory DLBCL and Durable Responses in Important DLBCL Patient Subgroups, Including Those with Primary ...

Zacks Investment Research - 5 months ago

Karyopharm (KPTI) commences a phase I/II study evaluating Xpovio (selinexor) in combination with standard-of-care therapy in patients with newly-diagnosed or recurrent glioblastoma.

GlobeNewsWire - 5 months ago

NEWTON, Mass., June 09, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced dosing of the first patient in a Pha...

Zacks Investment Research - 6 months ago

Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.

GlobeNewsWire - 6 months ago

NEWTON, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of ...

GlobeNewsWire - 6 months ago

-- Combination of Once-Weekly XPOVIO® (selinexor), Once-Weekly Velcade® (bortezomib) and Dexamethasone (SVd) Prolonged Median Progression-Free Survival by 47% Compared to Standard Twice-Weekl...

GlobeNewsWire - 6 months ago

NEWTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven  pharmaceutical company, today announced it has submitted a supplemental New ...

Seeking Alpha - 6 months ago

KPTI Has sNDAs In Process That Could More Than Double Its Share Price If Approved

GlobeNewsWire - 6 months ago

NEWTON, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced a new initiative to donate and distri...

Seeking Alpha - 6 months ago

Karyopharm Therapeutics Inc. (KPTI) CEO Michael Kauffman on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -11.43% and -15.99%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for...

Benzinga - 6 months ago

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) fell 9% in pre-market trading after the company reported Q1 results.

About KPTI

Karyopharm Therapeutics, a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor) tablets for the treatment of patients with heavily pretreated multiple myeloma. The company develops BOSTON, which is in Phase 3 clin... [Read more...]

Industry
Biotechnology
IPO Date
Nov 6, 2013
CEO
Michael Kauffman
Employees
347
Stock Exchange
NASDAQ
Ticker Symbol
KPTI
Full Company Profile

Financial Performance

In 2019, KPTI's revenue was $40.89 million, an increase of 34.80% compared to the previous year's $30.34 million. Losses were -$199.59 million, 11.9% more than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for KPTI is 31.00, which is an increase of 90.01% from the latest price.

Price Target
$31.00
(90.01% upside)